We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat
Read MoreHide Full Article
PRA Health Sciences, Inc. rallies 4.3% on Nov 5 after reporting strong earnings results.
The company reported third-quarter 2020 EPS of $1.30, beating the Zacks Consensus Estimate by 15%. The bottom line, however, fell from the prior-year quarter tally by 1.5%.
The company recorded revenues of $796.3 million in the quarter under review, up 2% year over year and 3.8% at cc. The figure surpassed the Zacks Consensus Estimate by 3.7%.
Results in Detail
Segmental Analysis
Net new business at the Clinical Research segment came in at $737.9 million, indicating growth of 10.2% from the prior-year quarter. Through the segment, the company receives contracts to provide clinical research services, with payments based on fixed-fee or fee-for-service arrangements.
Revenues at the Clinical Research segment amounted to $732.1 million, up 1.8% year over year while revenues at the Data Solutions segment amounted to $64.2 million, up 4.1% year over year.
Direct Costs
Direct costs totaled $412.1 million in the quarter, up 5.9% from the prior-year quarter. Per management, the increase was primarily driven by a rise in labor-related costs at the Clinical Research and higher data costs in Data Solutions segments.
Margin Trend
Gross profit came in at $384.2 million, down 1.8%. Gross margin came in at 48.3%, highlighting a contraction of 188 basis points (bps).
Adjusted operating profit in the quarter grossed $268.8 million, down 9.1% from the year-ago quarter. Adjusted operating margin in the quarter was 33.8%, down 414 bps.
PRA Health Sciences, Inc. Price, Consensus and EPS Surprise
The company exited the third quarter of 2020 with cash and cash equivalents of $336.2 million, up from $168.2 million at the end of the second quarter.
Cumulative net cash provided by operating activities totaled $267.1 million compared with that of $65.9 million in the year-ago period.
2020 Guidance
For 2020, PRA Health raised revenue projection to $3.12-$3.15 billion. The Zacks Consensus Estimate for the same stands at $3.10 billion.
Adjusted EPS for 2020 is expected within $4.61 and $4.71 (compared to previous range of $4.35-$4.55). The Zacks Consensus Estimate for the same stands at $4.43.
Our Take
PRA Health ended the third quarter on a strong note. Solid performance by both the Clinical Research and Data Solutions segments is a major positive. PRA Health continues to gain from large pharmaceutical companies and is also well-poised on Contract Research Organization market prospects.
On the flip side, direct costs shot up in the quarter under review. Contraction in both margins is a concern as well.
Zacks Rank and Key Picks
PRA Health currently carries a Zacks Rank #3 (Hold).
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat
PRA Health Sciences, Inc. rallies 4.3% on Nov 5 after reporting strong earnings results.
The company reported third-quarter 2020 EPS of $1.30, beating the Zacks Consensus Estimate by 15%. The bottom line, however, fell from the prior-year quarter tally by 1.5%.
The company recorded revenues of $796.3 million in the quarter under review, up 2% year over year and 3.8% at cc. The figure surpassed the Zacks Consensus Estimate by 3.7%.
Results in Detail
Segmental Analysis
Net new business at the Clinical Research segment came in at $737.9 million, indicating growth of 10.2% from the prior-year quarter. Through the segment, the company receives contracts to provide clinical research services, with payments based on fixed-fee or fee-for-service arrangements.
Revenues at the Clinical Research segment amounted to $732.1 million, up 1.8% year over year while revenues at the Data Solutions segment amounted to $64.2 million, up 4.1% year over year.
Direct Costs
Direct costs totaled $412.1 million in the quarter, up 5.9% from the prior-year quarter. Per management, the increase was primarily driven by a rise in labor-related costs at the Clinical Research and higher data costs in Data Solutions segments.
Margin Trend
Gross profit came in at $384.2 million, down 1.8%. Gross margin came in at 48.3%, highlighting a contraction of 188 basis points (bps).
Adjusted operating profit in the quarter grossed $268.8 million, down 9.1% from the year-ago quarter. Adjusted operating margin in the quarter was 33.8%, down 414 bps.
PRA Health Sciences, Inc. Price, Consensus and EPS Surprise
PRA Health Sciences, Inc. price-consensus-eps-surprise-chart | PRA Health Sciences, Inc. Quote
Financial Update
The company exited the third quarter of 2020 with cash and cash equivalents of $336.2 million, up from $168.2 million at the end of the second quarter.
Cumulative net cash provided by operating activities totaled $267.1 million compared with that of $65.9 million in the year-ago period.
2020 Guidance
For 2020, PRA Health raised revenue projection to $3.12-$3.15 billion. The Zacks Consensus Estimate for the same stands at $3.10 billion.
Adjusted EPS for 2020 is expected within $4.61 and $4.71 (compared to previous range of $4.35-$4.55). The Zacks Consensus Estimate for the same stands at $4.43.
Our Take
PRA Health ended the third quarter on a strong note. Solid performance by both the Clinical Research and Data Solutions segments is a major positive. PRA Health continues to gain from large pharmaceutical companies and is also well-poised on Contract Research Organization market prospects.
On the flip side, direct costs shot up in the quarter under review. Contraction in both margins is a concern as well.
Zacks Rank and Key Picks
PRA Health currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc. (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) , each carrying a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>